

# Wirkstoffe zur Therapie und Prophylaxe der Malaria

August Stich, Würzburg, und Martin Schlitzer, Marburg\*

## Literatur

- Adehossi E, Parola P, Foucault C, Delmont J, et al. Three-day quinine-clindamycin treatment of uncomplicated falciparum malaria imported from the tropics. *Antimicrob Agents Chemother* 2003;47:1173.
- Ajdukiewicz KM, Ong EL. Management of vivax malaria with low sensitivity to primaquine. *J Infect* 2007;54:209–11.
- Alker AP, Mwapa V, Purfield A, Rogerson SJ, et al. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. *Antimicrob Agents Chemother* 2005;49:3919–21.
- Allouche A, Bailey W, Barton S, Bwika J, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. *Lancet* 2004;363:1843–8.
- Alvarez G, Pineros JG, Tobon A, Rios A, et al. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. *Am J Trop Med Hyg* 2006;75:605–9.
- Andersen SL, Oloo AJ, Gordon DM, Ragama OB, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. *Clin Infect Dis* 1998;26:146–50.
- Anderson AC. Targeting DHFR in parasitic protozoa. *Drug Discov Today* 2005;10:121–8.
- Anderson TJ, Nair S, Qin H, Singlam S, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? *Antimicrob Agents Chemother* 2004;48:2180–8.
- Andrade AA, de Pilla Varotti F, de Freitas IO, de Souza MV, et al. Enhanced activity of mefloquine and artesunic acid against Plasmodium falciparum in vitro and P. berghei in mice by combination with ciprofloxacin. *Eur J Pharmacol* 2007;558:194–8.
- Ansele JH, Anbazhagan M, Brun R, Easterbrook JD, et al. O-alkoxyamide prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. *J Med Chem* 2004;47:4335–8.
- Ashley E, McGready R, Proux S, Nosten F. Malaria. *Travel Med Infect Dis* 2006;4:159–73.
- Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, et al. How much fat is necessary to optimize lumefantrine oral bioavailability? *Trop Med Int Health* 2007;12:195–200.
- Ashley EA, Stepniewska K, Lindegardh N, McGready R, et al. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. *Trop Med Int Health* 2007;12:201–8.
- Ashley EA, White NJ. Artemisinin-based combinations. *Curr Opin Infect Dis* 2005;18:531–6.
- Atteke C, Ndong JM, Aubouy A, Maciejewski L, et al. In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooue region of Gabon. *J Antimicrob Chemother* 2003;51:1021–4.
- Baca AM, Sirawaraporn R, Turley S, Sirawaraporn W, et al. Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action. *J Mol Biol* 2000;302:1193–212.
- Baggish AL, Hill DR. Antiparasitic agent atovaquone. *Antimicrob Agents Chemother* 2002;46:1163–73.
- Baird JK. Effectiveness of antimalarial drugs. *New Engl J Med* 2005;352:1565–77.
- Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. *Curr Infect Dis Rep* 2007;9:39–46.
- Banerjee R, Goldberg DE. The Plasmodium food vacuole. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery*. 1st ed. Totowa, NJ, USA: Humana Press, 2001:43–63.
- Basco LK, Bickii J, Ringwald P. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. *Antimicrob Agents Chemother* 1998;42:2347–51.
- Basco LK, Le Bras J. In vitro activity of pyronaridine against African strains of Plasmodium falciparum. *Ann Trop Med Parasitol* 1992;86:447–54.
- Bathurst I, Hentschel C. Medicines for malaria venture: sustaining anti-malarial drug development. *Trends Parasitol* 2006;22:301–7.
- Batty KT, Thu LT, Davis TM, Ilett KF, et al. A pharmacokinetic and pharmacodynamic study of intravenous vs. oral artesunate in uncomplicated falciparum malaria. *Br J Clin Pharmacol* 1998;45:123–9.
- Berman J. Toxicity of commonly-used antimalarial drugs. *Travel Med Infect Dis* 2004;2:171–84.
- Berry A, Senescau A, Lelievre J, Benoit-Vical F, et al. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. *Trans R Soc Trop Med Hyg* 2006;100:986–8.
- Bhat BK, Seth M, Bhaduri AP. Recent developments in 8-aminoquinoline antimalarials. *Prog Drug Res* 1984;28:197–231.
- Bhattacharjee AK, Karle JM. Functional correlation of molecular electronic properties with potency of synthetic carbinolamine antimalarial agents. *Bioorg Med Chem* 1998;6:1927–33.
- Biagini GA, O'Neill PM, Bray PG, Ward SA. Current drug development portfolio for antimalarial therapies. *Curr Opin Pharmacol* 2005;5:473–8.
- Biagini GA, Richier E, Bray PG, Calas M, et al. Heme binding contributes to antimalarial activity of bis-quaternary ammoniums. *Antimicrob Agents Chemother* 2003;47:2584–9.
- Biot C, Glorian G, Maciejewski LA, Brocard JS. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. *J Med Chem* 1997;40:3715–8.
- Bioland PB. Drug resistance in malaria. WHO 2001: Report No. WHO/CDS/DRS2001.4 Contract No.: Document Number.
- Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). *Am J Trop Med Hyg* 2007;76:208–23.
- Borrmann S, Adegnika AA, Matsiegui PB, Issifou S, et al. Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children. *J Infect Dis* 2004;189:901–8.
- Borrmann S, Adegnika AA, Moussavou F, Oyakhrome S, et al. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. *Antimicrob Agents Chemother* 2004;48:3749–54.
- Borrmann S, Lundgren I, Oyakhrome S, Impouma B, et al. Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. *Antimicrob Agents Chemother* 2005;50:2713–8.
- Bray PG, Martin RE, Tilley L, Ward SA, et al. Defining the role of PfcRT in Plasmodium falciparum chloroquine resistance. *Mol Microbiol* 2005;56:323–33.
- Bray PG, Ward SA, O'Neill PM. Quinolines and artemisinin: chemistry, biology and history. *Curr Top Microbiol Immunol* 2005;295:3–38.
- Brockman A, Price RN, van Vugt M, Heppner DG, et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. *Trans R Soc Trop Med Hyg* 2000;94:537–44.
- Brodersen DE, Clemons WM Jr., Carter AP, Morgan-Warren RJ, et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. *Cell* 2000;103:1143–54.
- Brueckner RP, Ohrt C, Baird JK, Milhous WK. 8-Aminoquinolines. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of ac-*

Priv.-Doz. Dr. August Stich, Tropenmedizinische Abteilung, Missionsärztliche Klinik gGmbH, Salvatorstr. 7, 97074 Würzburg, E-Mail: stich@missioklinik.de  
Prof. Dr. Martin Schlitzer, Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35032 Marburg, E-Mail: schlitzer@staff.uni-marburg.de

\*Modifizierte Fassung aus: *Chemother J* 2008;17:37–56.

- tion, resistance and new directions in drug discovery. 1st ed. Totowa, New Jersey, USA: Humana Press, 2001:123–51.
42. Bukirwa H, Garner P, Critchley J. Chlorproguanil-dapsone for treating uncomplicated malaria. *Cochrane Database Syst Rev* (Online) 2004; CD004387.
  43. Burkhardt D, Wiesner J, Stoesser N, Ramharter M, et al. Delayed parasite elimination in human infections treated with clindamycin parallels „delayed death” of *Plasmodium falciparum* in vitro. *Int J Parasitol* 2007;37:777–85.
  44. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against *Plasmodium falciparum* in vitro. *Exp Parasitol* 1995;80:373–81.
  45. Malaria-Treatment Guidelines [database on the Internet]. Department of Health and Human Services. Available from: <http://www.cdc.gov/malaria/>.
  46. Chan DC, Anderson AC. Towards species-specific antifolates. *Curr Med Chem* 2006;13:377–98.
  47. Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. *Infect Dis Clin North Am*. 200;19:185–210.
  48. Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. *JAMA* 2006;296:2234–44.
  49. Clark RL, White TE, S AC, Gaunt I, et al. Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. *Birth Defects Res* 2004;71:380–94.
  50. Clough B, Wilson RJM. Antibiotics and the plasmodial plastid organelle. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery*. 1st ed. Totowa, NJ, USA: Humana Press, 2001:265–86.51. Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. *Am J Trop Med Hyg* 1963;12:121–8.
  52. Connor BA. Achieving immunization in adults: opportunities presented by travel clinics in the US. *J Travel Med* 2001;8(Suppl 1):S17–9.
  53. Crockett M, Kain KC. Tafenoquine: a promising new antimalarial agent. *Exp Opin Investig Drugs* 2007;16:705–15.
  54. Curtis J, Maxwell CA, Msuya FH, Mkongewa S, et al. Mutations in dhfr in *Plasmodium falciparum* infections selected by chlorproguanil-dapsone treatment. *J Infect Dis* 2002;186:1861–4.
  55. Dahl EL, Shock JL, Shenai BR, Gut J, et al. Tetracyclines specifically target the apicoplast of the malaria parasite *Plasmodium falciparum*. *Antimicrob Agents Chemother* 2006;50:3124–31.
  56. Davis TM, Hung TY, Sim IK, Karunajeewa HA, et al. Piperaquine: a resurgent antimalarial drug. *Drugs* 2005;65:75–87.
  57. de Beer TA, Louw AI, Joubert F. Elucidation of sulfadoxine resistance with structural models of the bifunctional *Plasmodium falciparum* dihydropterin pyrophosphokinase-dihydropteroate synthase. *Bioorg Med Chem* 2006;14:4433–43.
  58. Delhaes L, Abessolo H, Biot C, Berry L, et al. In vitro and in vivo antimalarial activity of ferrochloroquine, a ferrocenyl analogue of chloroquine against chloroquine-resistant malaria parasites. *Parasitol Res* 2001;87:239–44.
  59. Denis MB, Davis TM, Hewitt S, Incardona S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated *falciparum* malaria. *Clin Infect Dis* 2002;35:1469–76.
  60. Denis MB, Tsuyuoka R, Lim P, Lindegardh N, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated *falciparum* malaria in northwest Cambodia. *Trop Med Int Health* 2006;11:1800–7.
  61. Divo AA, Sartorelli AC, Patton CL, Bia FJ. Activity of fluoroquinolone antibiotics against *Plasmodium falciparum* in vitro. *Antimicrob Agents Chemother* 1988;32:1182–6.
  62. Dondorp A, Nosten F, Stepniewska K, Day N, et al. Artesunate versus quinine for treatment of severe *falciparum* malaria: a randomised trial. *Lancet* 2005;366:717–25.
  63. DTG. [cited]; Available from: <http://leitlinien.net/042-001.htm>.
  64. Dunne MW, Singh N, Shukla M, Valecha N, et al. A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of *Plasmodium vivax* malaria in India. *Am J Trop Med Hyg* 2005;73:1108–11.
  65. Duraisingh MT, Cowman AF. Contribution of the *pfmdr1* gene to antimalarial drug-resistance. *Acta Trop* 2005;94:181–90.
  66. Duraisingh MT, Jones P, Sambou I, von Seidlein L, et al. The tyrosine-86 allele of the *pfmdr1* gene of *Plasmodium falciparum* is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. *Mol Biochem Parasitol* 2000;108:13–23.
  67. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, et al. Artemisinins target the SERCA of *Plasmodium falciparum*. *Nature* 2003;424:957–61.
  68. Edstein MD, Kocisko DA, Walsh DS, Eamsila C, et al. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis. *Clin Infect Dis* 2003;37:1654–8.
  69. Egan TJ. Haemozoin (malaria pigment): a unique crystalline drug target. *Targets [Review]* 2003;2:115–24.
  70. Ezzet F, van Vugt M, Nosten F, Loareesuwan S, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute *falciparum* malaria. *Antimicrob Agents Chemother* 2000;44:697–704.
  71. Famin O, Ginsburg H. Differential effects of 4-aminoquinoline-containing antimalarial drugs on hemoglobin digestion in *Plasmodium falciparum*-infected erythrocytes. *Biochem Pharmacol* 2002;63:393–8.
  72. Farnert A, Tengstam K, Palme IB, Bronner U, et al. Polyclonal *Plasmodium falciparum* malaria in travelers and selection of antifolate mutations after proguanil prophylaxis. *Am J Trop Med Hyg* 2002;66:487–91.
  73. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. *Life Sci* 2004;74:1957–72.
  74. Fivelman QL, Adagu IS, Warhurst DC. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of *Plasmodium falciparum*. *Antimicrob Agents Chemother* 2004;48:4097–102.
  75. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, et al. Malarone treatment failure and in vitro confirmation of resistance of *Plasmodium falciparum* isolate from Lagos, Nigeria. *Malar J* 2002;1:1.
  76. Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. *Pharmacol Ther* 1998;79:55–87.
  77. Franco-Paredes C, Santos-Preciado JL. Problem pathogens: prevention of malaria in travellers. *Lancet Infect Dis* 2006;6:139–49.
  78. Frederich M, Dogne JM, Angenot L, De Mol P. New trends in anti-malarial agents. *Curr Med Chem* 2002;9:1435–56.
  79. Genton B, Mueller I, Betuela I, Casey G, et al. Rifampicin/cotrimoxazole/isoniazid versus mefloquine or quinine + sulfadoxine-pyrimethamine for malaria: a randomized trial. *PLoS Clinical Trials* 2006;1:e38.
  80. Gao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. *Clin Pharmacokinet* 2001;40:343–73.
  81. Ginsburg H. Should chloroquine be laid to rest? *Acta Tropica* 2005;96:16–23.
  82. Gligorijevic B, McAllister R, Urbach JS, Roepe PD. Spinning disk confocal microscopy of live, intraerythrocytic malarial parasites. 1. Quantification of hemozoin development for drug sensitive versus resistant malaria. *Biochemistry* 2006;45:12400–10.
  83. Golenser J, Waknine JH, Krugliak M, Hunt NH, et al. Current perspectives on the mechanism of action of artemisinins. *Int J Parasitol* 2006;36:1427–41.
  84. Goodman CD, Su V, McFadden GL. The effects of anti-bacterials on the malaria parasite *Plasmodium falciparum*. *Mol Biochem Parasitol* 2007;152:181–91.
  85. Greenwood D. Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war. *J Antimicrob Chemother* 1995;36:857–72.
  86. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. *Pharmacol Rev* 2005;57:117–45.
  87. Guerra CA, Hay SI, Lucio-Paredes LS, Gikandi PW, et al. Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. *Malaria J* 2007;6:17.
  88. Guinovart C, Navia MM, Tanner M, Alonso PL. Malaria: burden of disease. *Curr Mol Med* 2006;6:137–40.
  89. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant *Plasmodium falciparum* and *Plasmodium vivax* malaria. *Clin Infect Dis* 2007;44:1067–74.
  90. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, et al. Antifolates can have a role in the treatment of *Plasmodium vivax*. *Trends Parasitol* 2007;23:213–22.
  91. Haynes RK. Artemisinin and derivatives: the future for malaria treatment? *Curr Opin Infect Dis* 2001;14:719–26.
  92. Haynes RK, Krishna S. Artemisinins: activities and actions. *Microbes Infect* 2004;6:1339–46.
  93. Haynes RK, Vonwiller SC. From Qinghao, marvelous herb of antiquity, to the antimalarial trioxane Qinghaosu. Some remarkable new chemistry. *Acc Chem Res* 1997;30:73–9.
  94. Heppner DG Jr., Walsh DS, Uthaimongkol N, Tang DB, et al. Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of *Plasmodium vivax* malaria in Western Thailand. *Am J Trop Med Hyg* 2005;73:842–9.
  95. Hill DR, Baird JK, Parise ME, Lewis LS, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. *Am J Trop Med Hyg* 2006;75:402–15.
  96. Hill DR, Ericsson CD, Pearson RD, Keystone JS, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2006;43:1499–539.
  97. Holmgren G, Gil JP, Ferreira PM, Veiga MI, et al. Amodiaquine resistant *Plasmodium falciparum* malaria in vivo is associated with selection of *pfprt* 76T and *pfmdr1* 86Y. *Infect Genet Evol* 2006;6:309–14.

98. Hoppe HC, van Schalkwyk DA, Wiehart UI, Meredith SA, et al. Antimalarial quinolines and artemisinin inhibit endocytosis in *Plasmodium falciparum*. *Antimicrob Agents Chemother* 2004;48:2370–8.
99. Hung TY, Davis TM, Ilett KF, Karunajeewa H, et al. Population pharmacokinetics of piperazine in adults and children with uncomplicated falciparum or vivax malaria. *Br J Clin Pharmacol* 2004;57:253–62.
100. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by *Plasmodium falciparum*. *Clin Pharmacol Ther* 1997;61:518–30.
101. Hutagalung R, Htoo H, Nwee P, Arunkamomkiri J, et al. A case-control auditory evaluation of patients treated with artemether-lumefantrine. *Am J Trop Med Hyg* 2006;74:211–4.
102. Hwang J, Bitarakwate E, Pai M, Reingold A, et al. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. *Trop Med Int Health* 2006;11:789–99.
103. Hyde JE, Sims PF. Sulfa-drug resistance in *Plasmodium falciparum*. *Trends Parasitol* 2001;17:265–6.
104. Jambou R, Legrand E, Niang M, Khim N, et al. Resistance of *Plasmodium falciparum* field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. *Lancet* 2005;366:1960–3.
105. Janssens B, van Herp M, Goubert L, Chan S, et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperazine for the treatment of uncomplicated falciparum malaria in Cambodia. *Trop Med Int Health* 2007;12:251–9.
106. Jiang H, Joy DA, Furuya T, Su XZ. Current understanding of the molecular basis of chloroquine-resistance in *Plasmodium falciparum*. *J Postgrad Med* 2006;52:271–6.
107. Johnson DJ, Fidock DA, Mungthin M, Lakshmanan V, et al. Evidence for a central role for PfCRT in conferring *Plasmodium falciparum* resistance to diverse antimalarial agents. *Mol Cell* 2004;15:867–77.
108. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. [see comment]. *Science* 1999;285:1573–6.
109. Jong EC, Nothdurft HD. Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety. *J Travel Med* 2001;8(Suppl 3):S48–56.
110. Kamiya T, Hashimoto M, Hemmi K, Takeno H, inventors; Fujisawa Pharmaceutical Company, Limited, assignee. Hydroxyaminohydrocarbonphosphonic acids. USA, 1978.
111. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, et al. Safety and efficacy of dihydroartemisinin/piperazine (Artekin) for the treatment of uncomplicated *Plasmodium falciparum* malaria in Rwandan children. *Trans R Soc Trop Med Hyg* 2006;100:1105–11.
112. Karle JM, Karle IL, Gerena L, Milhous WK. Stereochemical evaluation of the relative activities of the cinchona alkaloids against *Plasmodium falciparum*. *Antimicrob Agents Chemother* 1992;36:1538–44.
113. Karunajeewa HA, Reeder J, Lorry K, Dabod E, et al. Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea. *Antimicrob Agents Chemother* 2006;50:968–74.
114. Kazzim OJ, Adegbolagun OM, Osho O, Anumudu CI. Additive effects of ciprofloxacin on the in-vitro activity of chloroquine against a clinical isolate of *Plasmodium falciparum*. *Ann Trop Med Parasitol* 2006;100:579–84.
115. Kessl JJ, Ha KH, Merritt AK, Lange BB, et al. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in *Saccharomyces cerevisiae*. *J Biol Chem* 2005;280:17142–8.
116. Kessl JJ, Lange BB, Merbitz-Zahradnik T, Zwicker K, et al. Molecular basis for atovaquone binding to the cytochrome bc1 complex. *J Biol Chem* 2003;278:31312–8.
117. Kitchener S, Nasveld P, Edstein MD. Tafenoquine for the treatment of recurrent *Plasmodium vivax* malaria. *Am J Trop Med Hyg* 2007;76:494–6.
118. Kocken CH, van der Wel A, Arbe-Barnes S, Brun R, et al. *Plasmodium vivax*: in vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. *Exp Parasitol* 2006;113:197–200.
119. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. *Exp Opin Pharmacother* 2007;8:75–94.
120. Korsinczyk M, Fischer K, Chen N, Baker J, et al. Sulfadoxine resistance in *Plasmodium vivax* is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. *Antimicrob Agents Chemother* 2004;48:2214–22.
121. Kremsner PG, Krishna S. Antimalarial combinations. *Lancet* 2004;364:285–94.
122. Kremsner PG, Radloff P, Metzger W, Wildling E, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. *Antimicrob Agents Chemother* 1995;39:1603–5.
123. Krishna S, Uhlemann AC, Haynes RK. Artemisinins: mechanisms of action and potential for resistance. *Drug Resist Updat* 2004;7:233–44.
124. Krishna S, Woodrow CJ, Staines HM, Haynes RK, et al. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. *Trends Mol Med* 2006;12:200–5.
125. Krudsood S, Imwong M, Wilairatana P, Pukrittayakamee S, et al. Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. *Trans R Soc Trop Med Hyg* 2005;99:142–9.
126. Kuhn S, Gill MJ, Kain KC. Emergence of atovaquone-proguanil resistance during treatment of *Plasmodium falciparum* malaria acquired by a non-immune North American traveller to West Africa. *Am J Trop Med Hyg* 2005;72:407–9.
127. Kuhn Y, Rohrbach P, Lanzer M. Quantitative pH measurements in *Plasmodium falciparum*-infected erythrocytes using pHluorin. *Cell Microbiol* 2007;9:1004–13.
128. Kumar A, Katiyar SB, Agarwal A, Chauhan PM. Perspective in antimalarial chemotherapy. *Curr Med Chem* 2003;10:1137–50.
129. Lakshmanan V, Bray PG, Verdier-Pinard D, Johnson DJ, et al. A critical role for PfCRT K76T in *Plasmodium falciparum* verapamil-reversible chloroquine resistance. *EMBO J* 2005;24:2294–305.
130. Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, et al. UK malaria treatment guidelines. *J Infect* 2007;54:111–21.
131. Lang T, Greenwood B. The development of Lapdap, an affordable new treatment for malaria. *Lancet Infect Dis* 2003;3:162–8.
132. Legrand E, Demar M, Volney B, Ekala MT, et al. First case of emergence of atovaquone resistance in *Plasmodium falciparum* during second-line atovaquone-proguanil treatment in South America. *Antimicrob Agents Chemother* 2007;51:2280–1.
133. Lell B, Kremsner PG. Clindamycin as an antimalarial drug: review of clinical trials. *Antimicrob Agents Chemother* 2002;46:2315–20.
134. Leslie T, Mayan MI, Hasan MA, Safi MH, et al. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of *Plasmodium vivax* malaria in Afghanistan and Pakistan: a randomized controlled trial. *JAMA* 2007;297:2201–9.
135. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. *Malarone Clinical Trials Study Group*. *Am J Trop Med Hyg* 1999;60:533–41.
136. Looareesuwan S, Kyle DE, Viravan C, Vanijanonta S, et al. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. *Am J Trop Med Hyg* 1996;54:205–9.
137. Maguire JD, Sumawinata IW, Masbar S, Laksana B, et al. Chloroquine-resistant *Plasmodium malariae* in south Sumatra, Indonesia. *Lancet* 2002;360:58–60.
138. Maitland K, Makanga M, Williams TN. Falciparum malaria: current therapeutic challenges. *Curr Opin Infect Dis* 2004;17:405–12.
139. Mayengue PI, Kalmbach Y, Issifou S, Kremsner PG, et al. No variation in the prevalence of point mutations in the PfCRT and PfMDR1 genes in isolates from Gabonese patients with uncomplicated or severe *Plasmodium falciparum* malaria. *Parasitol Res* 2007;100:487–93.
140. Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperazine for the treatment of uncomplicated *Plasmodium falciparum* malaria in the Lao People's Democratic Republic (Laos). *Trop Med Int Health* 2006;11:1157–65.
141. Mberu EK, Nzila AM, Nduati E, Ross A, et al. *Plasmodium falciparum*: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance. *Exp Parasitol* 2002;101:90–6.
142. McCall MB, Beynon AJ, Mylanus EA, van der Ven AJ, et al. No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. *Trans R Soc Trop Med Hyg* 2006;100:1098–104.
143. McCollum AM, Poe AC, Hamel M, Huber C, et al. Antifolate resistance in *Plasmodium falciparum*: multiple origins and identification of novel dhfr alleles. *J Infect Dis* 2006;194:189–97.
144. McGready R, Ashley EA, Moo E, Cho T, et al. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. *J Infect Dis* 2005;192:846–53.
145. McGready R, Cho T, Samuel, Villegas L, et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. *Trans R Soc Trop Med Hyg* 2001;95:651–6.
146. McGready R, Keo NK, Villegas L, White NJ, et al. Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant *Plasmodium falciparum* malaria in pregnancy: a preliminary report. *Trans R Soc Trop Med Hyg* 2003;97:592–4.
147. McGready R, Stepniewska K, Lindegardh N, Ashley EA, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. *Eur J Clin Pharmacol* 2006;62:1021–31.
148. McIntyre JA, Castaner J, Bayes M. Tafenoquine succinate. *Drugs Future* 2003;28:859–69.

149. Menard D, Djalle D, Manirakiza A, Yapou F, et al. Drug-resistant malaria in Bangui, Central African Republic: an in vitro assessment. *Am J Trop Med Hyg* 2005;73:239–43.
150. Meshnick SR. Artemisinin and its derivatives. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery*. 1st ed. Totowa, NJ, USA: Humana Press, 2001:191–201.
151. Meshnick SR, Dobson MJ. The history of antimalarial drugs. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery*. 1st ed. Totowa, NJ, USA: Humana Press, 2001:15–25.
152. Metzger W, Mordmuller B, Graninger W, Bienzle U, et al. High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. *Antimicrob Agents Chemother* 1995;39:245–6.
153. Miller RS, Wongsrichanalai C, Buathong N, McDaniel P, et al. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. *Am J Trop Med Hyg* 2006;74:401–6.
154. Mita T, Kaneko A, Hombhanje F, Hwaihwanje I, et al. Role of pfm-dr1 mutations on chloroquine resistance in Plasmodium falciparum isolates with pfcrt K76T from Papua New Guinea. *Acta Tropica* 2006;98:137–44.
155. MMV. Press Release, November 15, 2005; Contract No.: Document Number.
156. MMV. Press Release, January 27, 2007; Contract No.: Document Number.
157. Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale – the „bashful“ malaria parasites. *Trends Parasitol* 2007;23:278–83.
158. Mzayek F, Deng H, Mather FJ, Wasilevich EC, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. *PLoS Clinical Trials* 2007;2:e6.
159. Nakornchai S, Konthiang P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. *Acta Trop* 2006;100:185–91.
160. Nasveld P, Kitchener S. Treatment of acute vivax malaria with tafenoquine. *Trans R Soc Trop Med Hyg* 2005;99:2–5.
161. Nduati EW, Kamau EM. Multiple synergistic interactions between atovaquone and antifolates against Plasmodium falciparum in vitro: a rational basis for combination therapy. *Acta Trop* 2006;97:357–63.
162. Newman RD, Parise ME, Slutsker L, Nahlen B, et al. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. *Trop Med Int Health* 2003;8:488–506.
163. Newton PN, Barnes KI, Smith PJ, Evans AC, et al. The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. *Eur J Clin Pharmacol* 2006;62:1003–9.
164. Nodiff EA, Chatterjee S, Musallam HA. Antimalarial activity of the 8-aminoquinolines. *Prog Med Chem* 1991;28:1–40.
165. Noedl H, Krudsood S, Chalermratana K, Silachamroon U, et al. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. *Clin Infect Dis* 2006;43:1264–71.
166. Noedl H, Krudsood S, Leowattana W, Tangpukdee N, et al. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. *Antimicrob Agents Chemother* 2007;51:651–6.
167. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. *J Antimicrob Chemother* 2006;57:1043–54.
168. Nzila A, Ochong E, Nduati E, Gilbert K, et al. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? *Trans R Soc Trop Med Hyg* 2005;99:341–6.
169. Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, et al. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorocycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. *Antimicrob Agents Chemother* 1998;42:164–9.
170. Obonyo CO, Juma EA, Ogutu BR, Vulule JM, et al. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. *Trans R Soc Trop Med Hyg* 2007;101:117–26.
171. Ohrt C, Willingmyre GD, Lee P, Knirsch C, et al. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. *Antimicrob Agents Chemother* 2002;46:2518–24.
172. Olliaro P, Nevill C, LeBras J, Ringwald P, et al. Systematic review of amodiaquine treatment in uncomplicated malaria.[see comment]. *Lancet* 1996;348:1196–201.
173. O'Neill PM, Posner GH. A medicinal chemistry perspective on artemisinin and related endoperoxides. *J Med Chem* 2004;47:2945–64.
174. O'Neill PM, Ward SA, Berry NG, Jayadevan JP, et al. A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. *Curr Topics Med Chem* 2006;6:479–507.
175. Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. *Nature* 2007;446:88–91.
176. Parenti MD, Pacchioni S, Ferrari AM, Rastelli G. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach. *J Med Chem* 2004;47:4258–67.
177. Parola P, Ranque S, Badiaga S, Niang M, et al. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. *Antimicrob Agents Chemother* 2001;45:932–5.
178. Pasvol G. The treatment of complicated and severe malaria. *Br Med Bull* 2005;75–76:29–47.
179. Patel O, Karnik K, Macreadie IG. Over-production of dihydrofolate reductase leads to sulfa-dihydropteroate resistance in yeast. *FEMS Microbiol Lett* 2004;236:301–5.
180. Patel OG, Mberu EK, Nzila AM, Macreadie IG. Sulfa drugs strike more than once. *Trends Parasitol* 2004;20:1–3.
181. Patel SN, Kain KC. Atovaquone/proguanil for the prophylaxis and treatment of malaria. *Expert Rev Antiinfect Ther* 2005;3:849–61.
182. Pimentel S, Nogueira F, Benchimol C, Quinhentos V, et al. Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola. *Malaria J* 2006;5:30.
183. Plowe CV. Folate antagonists and mechanism of resistance. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery*. 1st ed. Totowa, NJ, USA: Humana Press, 2001:173–90.
184. Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. *Nature Rev* 2005;3:870–81.
185. Posner GH, O'Neill PM. Knowledge of the proposed chemical mechanism of action and cytochrome P450 metabolism of antimalarial trioxanes like artemisinin allows rational design of new antimalarial peroxides. *Acc Chem Res* 2004;37:397–404.
186. Pradines B, Hovette P, Fusai T, Atanda HL, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. *J Clin Microbiol* 2006;44:2404–8.
187. Pradines B, Mabika Mamfoumbi M, Parzy D, Owono Medang M, et al. In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine. *Am J Trop Med Hyg* 1999;60:105–8.
188. Pradines B, Mamfoumbi MM, Tall A, Sokhna C, et al. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. *Antimicrob Agents Chemother* 2006;50:3225–6.
189. Pradines B, Rogier C, Fusai T, Mosnier J, et al. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. *Antimicrob Agents Chemother* 2001;45:1746–50.
190. Pradines B, Tall A, Parzy D, Spiegel A, et al. In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. *J Antimicrob Chemother* 1998;42:333–9.
191. Pradines B, Tall A, Ramiandrasoa F, Spiegel A, et al. In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. *J Antimicrob Chemother* 2006;57:1093–9.
192. Price RN, Uhlemann AC, Brockman A, McGready R, et al. Mefloquine resistance in Plasmodium falciparum and increased pfm-dr1 gene copy number. *Lancet*. 2004;364:438–47.
193. Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, et al. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. *Antimicrob Agents Chemother* 2000;44:2395–8.
194. Pukrittayakamee S, Prakongpan S, Wanwimolruk S, Clemens R, et al. Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. *Antimicrob Agents Chemother* 2003;47:1509–13.
195. Radloff PD, Philipps J, Hutchinson D, Kreamsner PG. Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria. *Trans R Soc Trop Med Hyg* 1996;90:682.
196. Ramharther M, Noedl H, Winkler H, Graninger W, et al. In vitro activity and interaction of clindamycin combined with dihydroartemisinin against Plasmodium falciparum. *Antimicrob Agents Chemother* 2003;47:3494–9.
197. Ramharther M, Oyakhrome S, Klouwenberg PK, Adegnik AA, et al. Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. *Clin Infect Dis* 2005;40:1777–84.

198. Ramya TN, Mishra S, Karmodiya K, Surolia N, et al. Inhibitors of non-housekeeping functions of the apicoplast defy delayed death in *Plasmodium falciparum*. *Antimicrob Agents Chemother* 2007;51:307–16.
199. Ranque S, Badiaga S, Delmont J, Brouqui P. Triangular test applied to the clinical trial of azithromycin against relapses in *Plasmodium vivax* infections. *Malar J* 2002;1:13.
200. Rastelli G, Sirawaraporn W, Sompornpisut P, Vilaivan T, et al. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with *Plasmodium falciparum* dihydrofolate reductase: structural basis of antifolate resistance. *Bioorg Med Chem* 2000;8:1117–28.
201. Rathod PK, Phillips MA. Prized malaria drug target nailed. *Nat Struct Biol* 2003;10:316–8.
202. Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. *Nature* 2002;415:686–93.
203. Ridley RG, Hofheinz W, Matile H, Jaquet C, et al. 4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant *Plasmodium falciparum*. *Antimicrob Agents Chemother* 1996;40:1846–54.
204. Ringwald P, Bickii J, Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. *Lancet* 1996;347:24–8.
205. Ringwald P, Eboumbou EC, Bickii J, Basco LK. In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against *Plasmodium falciparum*. *Antimicrob Agents Chemother* 1999;43:1525–7.
206. RKI. Reiseassoziierte Infektionskrankheiten 2006. *Epidemiol Bull* 2007;376–83.
207. Roggero R, Zufferey R, Minca M, Richier E, et al. Unraveling the mode of action of the antimalarial choline analog G25 in *Plasmodium falciparum* and *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 2004;48:2816–24.
208. Rohrbach P, Sanchez CP, Hayton K, Friedrich O, et al. Genetic linkage of pfmdr1 with food vacuolar solute import in *Plasmodium falciparum*. *EMBO J* 2006;25:3000–11.
209. Rosenthal PJ, Meshnick SR. Hemoglobin catabolism and iron utilization by malaria parasites. *Mol Biochem Parasitol* 1996;83:131–9.
210. Rungsithunrat K, Na-Bangchang K, Hawkins VN, Mungthin M, et al. Sensitivity to antifolates and genetic analysis of *Plasmodium vivax* isolates from Thailand. *Am J Trop Med Hyg* 2007;76:1057–65.
211. Sachs J, Malaney P. The economic and social burden of malaria. [see comment]. *Nature* 2002;415:680–5.
212. Salom-Roig XJ, Hamze A, Calas M, Vial HJ. Dual molecules as new antimalarials. *Comb Chem High Throughput Screen* 2005;8:49–62.
213. Sato S, Wilson RJ. The plastid of *Plasmodium* spp.: a target for inhibitors. *Curr Top Microbiol Immunol* 2005;295:251–73.
214. Schmuck G, Roehrdanz E, Haynes RK, Kahl R. Neurotoxic mode of action of artemisinin. *Antimicrob Agents Chemother* 2002r;46:821–7.
215. Schoenhofer F. 40 Jahre Plasmochin®. *Arzneimittelforschung* 1965;10:1256–8.
216. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant *Plasmodium falciparum* malaria acquired by a non-immune traveler to East Africa. *Clin Infect Dis* 2003;37:450–1.
217. Shanks GD, Edstein MD. Modern malaria chemoprophylaxis. *Drugs* 2005;65:2091–110.
218. Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, et al. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. *J Biol Chem* 2007;282:2494–504.
219. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in *Plasmodium falciparum*. *Mol Microbiol* 2005;57:913–26.
220. Simpson JA, Agbenyega T, Barnes KI, Di Perri G, et al. Population pharmacokinetics of artesunate and dihydroartemisinin following intrarectal dosing of artesunate in malaria patients. *PLoS Medicine* 2006;3:e444.
221. Simpson JA, Hughes D, Manyando C, Bojang K, et al. Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. *Br J Clin Pharmacol* 2006;61:289–300.
222. Sirima SB, Gansane A. Artesunate-amodiaquine for the treatment of uncomplicated malaria. *Exp Opin Investig Drugs* 2007;16:1079–85.
223. Smithuis F, Kyaw MK, Phe O, Aye KZ, et al. Efficacy and effectiveness of dihydroartemisinin-piperazine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. *Lancet* 2006;367:2075–85.224. Snow RW, Guerra CA, Noor AM, Myint HY, et al. The global distribution of clinical episodes of *Plasmodium falciparum* malaria. [see comment]. *Nature* 2005;434:214–7.
225. Srivastava IK, Morrissey JM, Darrrouzet E, Daldal F, et al. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. *Mol Microbiol* 1999;33:704–11.
226. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. *Antimicrob Agents Chemother* 1999;43:1334–9.
227. Stocks PA, Raynes KJ, Bray PG, Park BK, et al. Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 *Plasmodium falciparum*. *J Med Chem* 2002;45:4975–83.
228. Stromberg A, Bjorkman A. Ciprofloxacin does not achieve radical cure of *Plasmodium falciparum* infection in Sierra Leone. *Trans R Soc Trop Med Hyg* 1992;86:373.
229. Suh KN, Kain KC, Keystone JS. Malaria. *CMAJ* 2004;170:1693–702.
230. Sweetman SC (editor). *Martindale: The Complete Drug Reference*. 34<sup>th</sup> ed. London, UK: Pharmaceutical Press, 2004.
231. Sweetman SC (editor). *Martindale: The Complete Drug Reference*. 35<sup>th</sup> ed. London, UK: Pharmaceutical Press, 2007.
232. Tagbor H, Bruce J, Browne E, Randal A, et al. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. *Lancet* 2006;368:1349–56.
233. Taylor WR, Richie TL, Fryauff DJ, Picarima H, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. *Clin Infect Dis* 1999;28:74–81.
234. Taylor WR, White NJ. Antimalarial drug toxicity: a review. *Drug Saf* 2004;27:25–61.
235. Tekwani BL, Walker LA. 8-Aminoquinolines: future role as antiprotozoal drugs. *Curr Opin Infect Dis* 2006;19:623–31.
236. Tilley L, Loria P, Foley M. Chloroquine and other quinoline antimalarials. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery*. 1st ed. Totowa, NJ, USA: Humana Press, 2001:87–121.
237. Toovey S. Artesunate versus quinine for severe falciparum malaria. *Lancet* 2006;367:111; author reply -2.
238. Touze JE, Heno P, Fourcade L, Deharo JC, et al. The effects of antimalarial drugs on ventricular repolarization. *Am J Trop Med Hyg* 2002;67:54–60.
239. Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. *Nat Struct Mol Biol* 2005;12:628–9.
240. Uhlemann AC, Krishna S. Antimalarial multi-drug resistance in Asia: mechanisms and assessment. *Curr Top Microbiol Immunol* 2005;295:39–53.
241. Uhlemann AC, McGready R, Ashley EA, Brockman A, et al. Intra-host selection of *Plasmodium falciparum* pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. *J Infect Dis* 2007;195:134–41.
242. Uhlemann AC, Ramharther M, Lell B, Kremsner PG, et al. Amplification of *Plasmodium falciparum* multidrug resistance gene 1 in isolates from Gabon. *J Infect Dis* 2005;192:1830–5.
243. Vaidya AB. Atovaquone-proguanil combination. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery*. 1st ed. Totowa, NJ, USA: Humana Press, 2001:203–18.
244. Vaidya AB. Mitochondrial and plastid functions as antimalarial drug targets. *Curr Drug Targets* 2004;4:11–23.
245. Vaidya AB, Mather MW. A post-genomic view of the mitochondrion in malaria parasites. *Curr Top Microbiol Immunol* 2005;295:233–50.
246. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. *Trends Pharmacol Sci* 2006;27:594–601.
247. van Vugt M, Leonardi E, Phaipun L, Slight T, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. *Clin Infect Dis* 2002;35:1498–504.
248. Vennerstrom JL, Nuzum EO, Miller RE, Dorn A, et al. 8-Aminoquinolines active against blood stage *Plasmodium falciparum* in vitro inhibit hematin polymerization. *Antimicrob Agents Chemother* 1999;43:598–602.
249. Vial H, Calas M. Inhibitors of phospholipid metabolism. In: Rosenthal PJ (editor). *Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery*. 1st ed. Totowa, NJ, USA: Humana Press, 2001:347–65.
250. Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, et al. Efficacy of monthly tafenoquine for prophylaxis of *Plasmodium vivax* and multidrug-resistant *P. falciparum* malaria. *J Infect Dis* 2004;190:1456–63.
251. Watt G, Shanks GD, Edstein MD, Pavanand K, et al. Ciprofloxacin treatment of drug-resistant falciparum malaria. *J Infect Dis* 1991;164:602–4.
252. Welles TE. Transporter of a malaria catastrophe. *Nat Med* 2004;10:1169–71.
253. Werbovets K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. *Curr Opin Investig Drugs* 2006;7:147–57.
254. Wernsdorfer WH. *Curr Opin Antiinfect Investig Drugs* 2000;2:88–98.
255. Wesche DL, Schuster BG, Wang WX, Woosley RL. Mechanism of cardiotoxicity of halofantrine. *Clin Pharmacol Ther* 2000;67:521–9.

256. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. *Antimicrob Agents Chemother* 1997;41:1413–22.
257. White NJ. Antimalarial drug resistance. *J Clin Invest* 2004;113:1084–92.
258. White NJ. Malaria – time to act.[comment]. *New Engl J Med* 2006;355:1956–7.
259. WHO. Susceptibility of *Plasmodium falciparum* to antimalarial drugs: Report on global monitoring: 1996–2004. Geneva, Switzerland, 2005.
260. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, et al. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of *Plasmodium falciparum* in Europe. *J Infect Dis* 2004;190:1541–6.
261. Wiesner J, Henschker D, Hutchinson DB, Beck E, et al. In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. *Antimicrob Agents Chemother* 2002;46:2889–4.
262. Wiesner J, Jomaa H. Isoprenoid biosynthesis of the apicoplast as drug target. *Curr Drug Targets* 2007;8:3–13.
263. Wiesner J, Seeber F. The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs. *Expert Opin Ther Targets* 2005;9:23–44.
264. Wilairatana P, Kyle DE, Loareesuwan S, Chinwongprom K, et al. Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. *Ann Trop Med Parasitol* 1997;91:125–32.
265. Wiegler A. Malaria und synthetische Malariamittel. *Angew Chem* 1949;61:49–80.
266. Wistrom J, Norrby SR, Myhre EB, Eriksson S, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. *J Antimicrob Chemother* 2001;47:43–50.
267. Woodrow CJ, Haynes RK, Krishna S. Artemisinins. *Postgrad Med J* 2005;81:71–8.
268. Woodrow CJ, Krishna S. Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. *Cell Mol Life Sci* 2006;63:1586–96.
269. Woodrow CJ, Planche T, Krishna S. Artesunate versus quinine for severe falciparum malaria. *Lancet* 2006;367:110–1; author reply 1–2.
270. Yeramian P, Meshnick SR, Krudsood S, Chalermrut K, et al. Efficacy of DB289 in Thai patients with *Plasmodium vivax* or acute, uncomplicated *Plasmodium falciparum* infections. *J Infect Dis* 2005;192:319–22.
271. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, et al. Insights into antifolate resistance from malarial DHFR-TS structures. *Nat Struct Biol* 2003;10:357–65.
272. Zhang Y, Meshnick SR. Inhibition of *Plasmodium falciparum* dihydropteroate synthetase and growth in vitro by sulfa drugs. *Antimicrob Agents Chemother* 1991;35:267–71.